Crystal structure of the DNA deaminase APOBEC3B catalytic domain

Journal of Biological Chemistry

Volumn 290, Issue 47, 2015, Pages 28120-28130

  Shi, Ke ^a,b,c   Carpenter, Michael A ^a,b,c   Kurahashi, Kayo ^a,b,c   Harris, Reuben S ^a,b,c   Aihara, Hideki ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DNA; DRUG THERAPY; MUTAGENESIS; NUCLEOTIDES; SITE SELECTION; TUMORS;

ADVERSE OUTCOMES; ANTICANCER DRUG; CATALYTIC DOMAINS; HIGH RESOLUTION CRYSTAL STRUCTURE; MECHANISTIC STUDIES; MULTIPLE CRYSTALS; MUTATION ANALYSIS; SINGLE-STRANDED DNA;

CRYSTAL STRUCTURE;

DEAMINASE; DNA DEAMINASE APOBEC3B; RIFAMPICIN; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; MINOR HISTOCOMPATIBILITY ANTIGEN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; APOBEC3B CATALYTIC DOMAIN; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEAMINATION; DRUG RESISTANCE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; EXPERIMENTAL DESIGN; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTAGENESIS; MUTATION RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DNA BINDING; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SOLUBILITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; CHEMISTRY; ENZYME STABILITY; HUMAN; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; CYTIDINE DEAMINASE; ENZYME STABILITY; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; MODELS, MOLECULAR; PROTEIN CONFORMATION; SOLUBILITY;

EID: 84947771457     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.679951     Document Type: Article

References (65)

1. Conticello, S. G. (2008) The AID/APOBEC family of nucleic acid mutators. Genome Biol. 9, 229
2. Refsland, E. W., and Harris, R. S. (2013) The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 371, 1-27
3. Harris, R. S., and Dudley, J. P. (2015) APOBECs and virus restriction. Virology 479-480, 131-145
4. Desimmie, B. A., Delviks-Frankenberrry, K. A., Burdick, R. C., Qi, D., Izumi, T., and Pathak, V. K. (2014) Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J. Mol. Biol. 426, 1220-1245
5. Bogerd, H. P., Wiegand, H. L., Hulme, A. E., Garcia-Perez, J. L., O'Shea, K. S., Moran, J. V., and Cullen, B. R. (2006) Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 103, 8780-8785
6. Lackey, L., Law, E. K., Brown, W. L., and Harris, R. S. (2013) Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle 12, 762-772
7. Di Noia, J. M., and Neuberger, M. S. (2007) Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1-22
8. Robbiani, D. F., and Nussenzweig, M. C. (2013) Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu. Rev. Pathol. 8, 79-103
9. Fossat, N., and Tam, P. P. (2014) Re-editing the paradigm of cytidine (C) to uridine (U) RNA editing. RNA Biol. 11, 1233-1237
10. Smith, H. C., Bennett, R. P., Kizilyer, A., McDougall, W. M., and Prohaska, K. M. (2012) Functions and regulation of the APOBEC family of proteins. Semin. Cell Dev. Biol. 23, 258-268
11. Stenglein, M. D., Matsuo, H., and Harris, R. S. (2008) Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J. Virol. 82, 9591-9599
12. Pak, V., Heidecker, G., Pathak, V. K., and Derse, D. (2011) The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J. Virol. 85, 8538-8547
13. Lackey, L., Demorest, Z. L., Land, A. M., Hultquist, J. F., Brown, W. L., and Harris, R. S. (2012) APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 419, 301-314
14. Swanton, C., McGranahan, N., Starrett, G. J., and Harris, R. S. (2015) APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704-712
15. Roberts, S. A., and Gordenin, D. A. (2014) Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786-800
16. Henderson, S., and Fenton, T. (2015) APOBEC3 genes: retroviral restriction factors to cancer drivers. Trends Mol. Med. 21, 274-284
17. Burns, M. B., Lackey, L., Carpenter, M. A., Rathore, A., Land, A. M., Leonard, B., Refsland, E. W., Kotandeniya, D., Tretyakova, N., Nikas, J. B., Yee, D., Temiz, N. A., Donohue, D. E., McDougle, R. M., Brown, W. L., Law, E. K., and Harris, R. S. (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366-370
18. Burns, M. B., Temiz, N. A., and Harris, R. S. (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977-983
19. Roberts, S. A., Lawrence, M. S., Klimczak, L. J., Grimm, S. A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G. V., Carter, S. L., Saksena, G., Harris, S., Shah, R. R., Resnick, M. A., Getz, G., and Gordenin, D. A. (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970-976
20. Henderson, S., Chakravarthy, A., Su, X., Boshoff, C., and Fenton, T. R. (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7, 1833-1841
21. Leonard, B., Hart, S. N., Burns, M. B., Carpenter, M. A., Temiz, N. A., Rathore, A., Vogel, R. I., Nikas, J. B., Law, E. K., Brown, W. L., Li, Y., Zhang, Y., Maurer, M. J., Oberg, A. L., Cunningham, J. M., Shridhar, V., Bell, D. A., April, C., Bentley, D., Bibikova, M., Cheetham, R. K., Fan, J. B., Grocock, R., Humphray, S., Kingsbury, Z., Peden, J., Chien, J., Swisher, E. M., Hartmann, L. C., Kalli, K. R., Goode, E. L., Sicotte, H., Kaufmann, S. H., and Harris, R. S. (2013) APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 73, 7222-7231
22. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A. L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R., Desmedt, C., Eils, R., Eyfjörd, J. E., Foekens, J. A., Greaves, M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jäger, N., Jones, D. T., Jones, D., Knappskog, S., Kool, M., Lakhani, S. R., López-Otín, C., Martin, S., Munshi, N. C., Nakamura, H., Northcott, P. A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J. V., Puente, X. S., Raine, K., Ramakrishna, M., Richardson, A. L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T. N., Span, P. N., Teague, J. W., Totoki, Y., Tutt, A. N., Valdes-Mas, R., van Buuren, M. M., van't Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L. R., Zucman-Rossi, J., Futreal, P. A., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S. M., Siebert, R., Campo, E., Shibata, T., Pfister, S. M., Campbell, P. J., and Stratton, M. R. (2013) Signatures of mutational processes in human cancer. Nature 500, 415-421
23. de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., Grönroos, E., Muhammad, M. A., Horswell, S., Gerlinger, M., Varela, I., Jones, D., Marshall, J., Voet, T., Van Loo, P., Rassl, D. M., Rintoul, R. C., Janes, S. M., Lee, S. M., Forster, M., Ahmad, T., Lawrence, D., Falzon, M., Capitanio, A., Harkins, T. T., Lee, C. C., Tom, W., Teefe, E., Chen, S. C., Begum, S., Rabinowitz, A., Phillimore, B., Spencer-Dene, B., Stamp, G., Szallasi, Z., Matthews, N., Stewart, A., Campbell, P., and Swanton, C. (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256
24. Sieuwerts, A. M., Willis, S., Burns, M. B., Look, M. P., Meijer-Van Gelder, M. E., Schlicker, A., Heideman, M. R., Jacobs, H., Wessels, L., Leyland-Jones, B., Gray, K. P., Foekens, J. A., Harris, R. S., and Martens, J. W. (2014) Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Hormones Cancer 5, 405-413
25. Cescon, D. W., Haibe-Kains, B., and Mak, T. W. (2015) APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl. Acad. Sci. U.S.A. 112, 2841-2846
26. Xu, L., Chang, Y., An, H., Zhu, Y., Yang, Y., and Xu, J. (2015) High APOBEC3B expression is a predictor of recurrence in patients with lowrisk clear cell renal cell carcinoma. Urol. Oncol. 33, e1-e8
27. Walker, B. A., Wardell, C. P., Murison, A., Boyle, E. M., Begum, D. B., Dahir, N. M., Proszek, P. Z., Melchor, L., Pawlyn, C., Kaiser, M. F., Johnson, D. C., Qiang, Y. W., Jones, J. R., Cairns, D. A., Gregory, W. M., Owen, R. G., Cook, G., Drayson, M. T., Jackson, G. H., Davies, F. E., and Morgan, G. J. (2015) APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997
28. Kidd, J. M., Newman, T. L., Tuzun, E., Kaul, R., and Eichler, E. E. (2007) Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 3, e63
29. Bohn, M. F., Shandilya, S. M., Albin, J. S., Kouno, T., Anderson, B. D., McDougle, R. M., Carpenter, M. A., Rathore, A., Evans, L., Davis, A. N., Zhang, J., Lu, Y., Somasundaran, M., Matsuo, H., Harris, R. S., and Schiffer, C. A. (2013) Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 21, 1042-1050
30. Chen, K. M., Harjes, E., Gross, P. J., Fahmy, A., Lu, Y., Shindo, K., Harris, R. S., and Matsuo, H. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119
31. Harjes, E., Gross, P. J., Chen, K. M., Lu, Y., Shindo, K., Nowarski, R., Gross, J. D., Kotler, M., Harris, R. S., and Matsuo, H. (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J. Mol. Biol. 389, 819-832
32. Kouno, T., Luengas, E. M., Shigematsu, M., Shandilya, S. M., Zhang, J., Chen, L., Hara, M., Schiffer, C. A., Harris, R. S., and Matsuo, H. (2015) Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat. Struct. Mol. Biol. 22, 485-491
33. Shandilya, S. M., Nalam, M. N., Nalivaika, E. A., Gross, P. J., Valesano, J. C., Shindo, K., Li, M., Munson, M., Royer, W. E., Harjes, E., Kono, T., Matsuo, H., Harris, R. S., Somasundaran, M., and Schiffer, C. A. (2010) Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18, 28-38
34. Byeon, I. J., Ahn, J., Mitra, M., Byeon, C. H., Hercík, K., Hritz, J., Charlton, L. M., Levin, J. G., and Gronenborn, A. M. (2013) NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. Nat. Commun. 4, 1890
35. Kitamura, S., Ode, H., Nakashima, M., Imahashi, M., Naganawa, Y., Kurosawa, T., Yokomaku, Y., Yamane, T., Watanabe, N., Suzuki, A., Sugiura, W., and Iwatani, Y. (2012) The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 19, 1005-1010
36. Krzysiak, T. C., Jung, J., Thompson, J., Baker, D., and Gronenborn, A. M. (2012) APOBEC2 is a monomer in solution: implications for APOBEC3G models. Biochemistry 51, 2008-2017
37. Holden, L. G., Prochnow, C., Chang, Y. P., Bransteitter, R., Chelico, L., Sen, U., Stevens, R. C., Goodman, M. F., and Chen, X. S. (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456, 121-124
38. Siu, K. K., Sultana, A., Azimi, F. C., and Lee, J. E. (2013) Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun. 4, 2593
39. Li, M., Shandilya, S. M., Carpenter, M. A., Rathore, A., Brown, W. L., Perkins, A. L., Harki, D. A., Solberg, J., Hook, D. J., Pandey, K. K., Parniak, M. A., Johnson, J. R., Krogan, N. J., Somasundaran, M., Ali, A., Schiffer, C. A., and Harris, R. S. (2012) First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 7, 506-517
40. Bohn, M. F., Shandilya, S. M., Silvas, T. V., Nalivaika, E. A., Kouno, T., Kelch, B. A., Ryder, S. P., Kurt-Yilmaz, N., Somasundaran, M., and Schiffer, C. A. (2015) The ssDNA mutator APOBEC3A is regulated by cooperative dimerization. Structure 23, 903-911
41. Stenglein, M. D., Burns, M. B., Li, M., Lengyel, J., and Harris, R. S. (2010) APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17, 222-229
42. Carpenter, M. A., Li, M., Rathore, A., Lackey, L., Law, E. K., Land, A. M., Leonard, B., Shandilya, S. M., Bohn, M. F., Schiffer, C. A., Brown, W. L., and Harris, R. S. (2012) Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J. Biol. Chem. 287, 34801-34808
43. Otwinowski, Z., and Minor, W. (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326
44. Kabsch, W. (2010) XDS. Acta Crystallogr. D. Biol. Crystallogr. 66, 125-132
45. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674
46. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132
47. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221
48. Halgren, T. A. (2009) Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model. 49, 377-389
49. Harris, R. S., Petersen-Mahrt, S. K., and Neuberger, M. S. (2002) RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247-1253
50. Haché, G., Liddament, M. T., and Harris, R. S. (2005) The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280, 10920-10924
51. Bogerd, H. P., Wiegand, H. L., Doehle, B. P., and Cullen, B. R. (2007) The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364, 486-493
52. McDougle, R. M., Hultquist, J. F., Stabell, A. C., Sawyer, S. L., and Harris, R. S. (2013) D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B. Virology 441, 31-39
53. Rathore, A., Carpenter, M. A., Demir, Ö., Ikeda, T., Li, M., Shaban, N. M., Law, E. K., Anokhin, D., Brown, W. L., Amaro, R. E., and Harris, R. S. (2013) The local dinucleotide preference of APOBEC3G can be altered from 5′-CC to 5′-TC by a single amino acid substitution. J. Mol. Biol. 425, 4442-4454
54. Li, J., Chen, Y., Li, M., Carpenter, M. A., McDougle, R. M., Luengas, E. M., Macdonald, P. J., Harris, R. S., and Mueller, J. D. (2014) APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. J. Mol. Biol. 426, 1296-1307
55. Carpenter, M. A., Rajagurubandara, E., Wijesinghe, P., and Bhagwat, A. S. (2010) Determinants of sequence-specificity within human AID and APOBEC3G. DNA Repair (Amst.) 9, 579-587
56. Wang, M., Rada, C., and Neuberger, M. S. (2010) Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID. J. Exp. Med. 207, 141-153
57. Kohli, R. M., Abrams, S. R., Gajula, K. S., Maul, R. W., Gearhart, P. J., and Stivers, J. T. (2009) A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J. Biol. Chem. 284, 22898-22904
58. Kohli, R. M., Maul, R. W., Guminski, A. F., McClure, R. L., Gajula, K. S., Saribasak, H., McMahon, M. A., Siliciano, R. F., Gearhart, P. J., and Stivers, J. T. (2010) Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J. Biol. Chem. 285, 40956-40964
59. Almog, R., Maley, F., Maley, G. F., Maccoll, R., and Van Roey, P. (2004) Three-dimensional structure of the R115E mutant of T4-bacteriophage 2′-deoxycytidylate deaminase. Biochemistry 43, 13715-13723
60. Betts, L., Xiang, S., Short, S. A., Wolfenden, R., and Carter, C. W., Jr. (1994) Cytidine deaminase. The 2.3 angstrom crystal structure of an enzyme: transition-state analog complex. J. Mol. Biol. 235, 635-656
61. Furukawa, A., Nagata, T., Matsugami, A., Habu, Y., Sugiyama, R., Hayashi, F., Kobayashi, N., Yokoyama, S., Takaku, H., and Katahira, M. (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J. 28, 440-451
62. Shindo, K., Li, M., Gross, P. J., Brown, W. L., Harjes, E., Lu, Y., Matsuo, H., and Harris, R. S. (2012) A Comparison of two single-stranded DNA binding models by mutational analysis of APOBEC3G. Biology 1, 260-276
63. Macbeth, M. R., Schubert, H. L., Vandemark, A. P., Lingam, A. T., Hill, C. P., and Bass, B. L. (2005) Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science 309, 1534-1539
64. Losey, H. C., Ruthenburg, A. J., and Verdine, G. L. (2006) Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nat. Struct. Mol. Biol. 13, 153-159
65. Johansson, E., Mejlhede, N., Neuhard, J., and Larsen, S. (2002) Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 angstrom resolution. Biochemistry 41, 2563-2570